The Obama administration recently placed India on a 'watch list' over its lack of intellectual property protection for innovator companies. Undaunted by US concerns, India continues to pursue its own public health interests, adopting policies that support the generics industry. Thus far, most of the companies affected have been big pharma rather than biotech, although Indian authorities have revoked patents on blockbuster biologics Pegasys and Herceptin (Table 1).
About this article
Cite this article
Melton, L. India's onslaught on drug patents continues. Nat Biotechnol 31, 869 (2013). https://doi.org/10.1038/nbt1013-869a